Figure 5.

Sunitinib sensitive cells response to tipifarnib and combination treatment. (A) Sub-confluent 786-O, A498, and Caki-2 cells were grown in 96-well plates and dosed with sunitinib alone, tipifarnib alone, or combination of both sunitinib and tipifarnib. After 48 h, MTT assay was implemented to assess viability. All assays were completed in triplicates. * p < 0.05, compared with the DMSO controls. (B) Cyclin D1 levels after sunitinib-alone treatment decrease. These levels further decrease after combination treatment with tipifarnib and sunitinib. The densitometric plots show fold decrease in the expression. GAPDH immunoblot was used as a loading control for each western blot and full blots are presented in Supplementary Figure S8. (C) Clonogenic assay was performed on all 3 SS cell lines and 293T set as our control. Colonies were counted 14 days after initial seeding. Each assay was completed in triplicate and repeated in at least three independent experiment batches. Representative results are shown, * p < 0.05, compared with the DMSO control groups, # p < 0.01, compared with the sunitinib groups, and δ p < 0.01, compared with the tipifarnib groups.